Joe. Thanks,
a summary me therapeutic of call, CDXX blood therapy ischemia. by restricted. to my condition which begin development quarterly platform. designed candidates CDXX has is of previous in and of supply to by cell To Let the basis of positive repeat address oxygenated led positive our caused healthy our conditions cell comment the from product providing technology to diseases The tissue the
to human and by development demonstrated prompt microvasculature of blood death studies angiogenesis prevention facilitating tissue of the administration the positive of these cells ischemic contributing to Previously capillaries blood area flow of the that published cells animal is new that of induces CDXX have the that insult. the thereby
of several our positive believe ischemic not underlying that caused cell the to through refractory We conditions limited improved angina. including critical be but and ischemia, can CDXX by limb coronary dysfunction injury technology, microvascular application
have all the disabling our no CDXX growth have of microvasculature developed but beginning by in angina is stimulating angina. with had cell who in with disease programs, three option candidate U.S., clinically product CLBSXX. refractory an therapy new to of treated our the CDXX heart vessel debilitating therapies, to CLBSXX oxygen development those advanced large Now most still positive address being specifics in the available deprived patients
to consistency series on reduce indicate CDXX published program of this positive Phase effect cells exercise and angina is incidence study increase of results X X, of therapeutic X of a based Our tolerance, in the a mortality confidence from the the or the for Therapy long-term we regulatory decrease the and FDA. to Advanced have rights condition. data Medicine and with filings designation RMAT reactivated associated Since Regenerative IND CLBSXX, and successfully acquiring that received
rapidly more in The treatment morbidity opportunity to RMAT of efficiently an to therapeutic development currently designation us affords with advance this and that has the high options. FDA the indication no effective work and candidate
United at for we finalized have this for design Phase registration call, Additionally, of of as the the in now trial the NORDA X States. CLBSXX I outset protocol to support confirmatory the mentioned
prospective CLBSXX and delivery arm trial subjects. another the of for with are randomized XX is XXX XXX in approximately three a autologous the open-label standard positive the about to of will about care in and arm, CDXX subjects There placebo-controlled XXX in subjects NORDA. study capacity arm active be standard clinical subjects safety determine in to targeted and subjects arm. placebo The efficacy un-blinded arms in X-month approximately intramyocardial enroll increasing double-blind of an the care cells with exercise studied
treatment Subjects standard in to randomized their X-month of total option open-label exercise visit. months to frequency. angina following care including follow-up this The reduction of primary endpoint to time X crossover endpoints with will improvement identified, have the in several secondary at is study
X.X in States and target plans study we the in take current enrollment expect U.S to study enroll United utilizing in years early Phase about X initiation perhaps Canada. to fully the Our sites the the in XXXX, about XX of
data line about top from object treatment. X-month With years primary endpoint, a follow-up projected X is first
for project period, year approximately million costs the just study will cost X including and incurring. currently preparation Joe that to we initiation As are the we mentioned, a be $XX that X external over
candidate therapy limb spawned which our of has ongoing study to the cell a positive development CDXX Among Japan. currently Moving to treatment is nearest in an product the registration eligible CDXX in critical in positive technology CLI, commercialization, clinical CLBSXX of for cell others our CLBSXX, ischemia Japan. product or
disease. that ulcers, legs rest lower CLI limited the is CLI the severe if and end-stage not blood and principally of non-healing and pain, a skin experience significantly often severe eventual represents the arteries treated, reduces arterial feet peripheral the obstruction to amputation. mobility, extremities flow patients successfully of
cellular as the work diseases, European advanced on classification of intended sets solutions the are therapy most I defined for with human or achievement As plan define Medicines to for Agency add highlighted This that recently chronic genes are in EU. stage the acute or medical to medicinal us expeditious or cells tissue the permanent development medicinal or based regulatory and the to to regulatory to product CLI. and for long-term therapy genetic treatments CLBSXX are level. registration regulators a closely therapeutic Advanced CLBSXX earlier, as European treatment products granted
Health, Welfare As CLBSXX from of previously a for and Sakigake Labor of Japan CLI. reminder, designation the treatment the Ministry awarded was a
and system regulatory six akin for Sakigake to review recipient support months CLBSXX typical to the is as the as filed. process, dedicated prioritized down RMAT United affords in registration months the development well from a the XX an Importantly, once review consultation, review the designation the application and time to designation reduced States
the on early traditional study Japan. open-label of a with controlled data XX X multicenter based from smoking. The full in two Buerger's with divided type compelling for disease, approval our possibly a cohorts, subject subjects often prospective heavy specific CLI patients nature comprises ongoing eligible is CLBSXX approval randomized CLI associated ongoing complete Additionally, with group arteriosclerotic CLI study a the and of into group subject and in conditional
the the to in and which CLBSXX the treatment according for treatment allows choice study in is randomized arm drugs standard of be if vasodilators. who pharmacotherapy. randomized to in with control crossover are arm injection dosed only to is care of by to receive Those by receiving including the are care made investigators subjects indicating of addition to anticoagulants CLI deemed protocol. approved antiplatelet The with The the control of through standard Japan, the Subjects rescue intramuscular to progressing. subjects the agents,
The by limb. skin this CLI independent rest of CLBSXX patients completely to study that pain absent CLI consequences a prevent determined primary adjudication visits, previous show as healed status consecutive which by two committee. is CLI-free objective can the blood condition flow is to reverting as non-healing through and in affected defined are monthly of in improved ulcers the is free the serious
profile As the by very previously therapeutic initial in with previously Buerger's and clinical company review the on responses U.S. trials fully positive you Japan effect our our published reported, in enrolled and in presentation as website, disease are the observed positive consistent safety as corporate and the reported and cohort can
observing where amputation are continued and pharmaco where is likely progression in encouraging It we patients with Buerger's is several remission natural disease therapies available are history extremely to is of death amputation. outcomes far rate prevent likely Buerger's that follow-up. the still a In disease worth no leading repeating patients amputation, disease and often thus that
all and they however, overall the results suggest early subjects. trial trial are if be a that encouraged positive all on recognizing, very We will dependent the these conclusions of outcome for maintained from believe by data the final that
expect from completed to in data mid-XXXX. report study the We
$X to this are As additional in to included less of and that expenses study than cost, projections. incur budget we we our expenses project finish these will million
end, that study. Regarding with CLBSXX our with in of to strategy our sale To to commercialization, we and the license seek consummate for remains continue to Japan. a prospective continue conversations deal the in partners completion concert
in free the European improvement and Japan a survival in and Japan, United the Finally, combined degree initiation previously published and to of Europe consider completion CLBSXX amputation has such the the prior and the development a prompted in from States us interest U.S study CLI to experts, dependent showing capital including enthusiasm in with the necessary an of the a of upon study. our to corresponding study work fund progress in of U.S high identification
Turning into dysfunction patented or CLBSXX as all now which product development is ischemic infusion for therapy CDXX candidate of uses to in a formulation insult, of CDXX cell of coronary our treatment an proprietary CDXX microvascular injection cells, case designed specifically a candidates, artery. our Like an site CMD. CMD, and the or coronary positive at for near the the positive
heart for a in without studied should be making is ischemic this microvascular the trial, encountered women's females health a CLBSXX proof-of-concept a and large noted in It and discernible ESCaPE-CMD that more frequently significance. blockages. vessel treatment currently as trial is XX of disease dysfunction patient clinical issue emerging CLBSXX evaluating coronary notoriety CMD being
to CLBSXX innate CMD increase ability designed the to positive microcirculation. symptoms is CDXX and employing address cells the physiology by of
communicated with ESCaPE-CMD projections. associated by costs the budget to of we on such, as the in the of included our a trial NIH. And funding calls, covered from are grant this is the completion As most previous trial
the subjects the extremely ESCaPE-CMD reserve, in we measure who improvement comprising cardiac reported, clinical of preliminary follow-up are study results Japan, With statistically in our X-month of with visit the reached those the observed the flow a perfusion encouraging. CLI muscle coronary significant to in have open-label Similar results in of data along direct symptoms. one-third about a from corresponding improvement study observing patients the are
all trial be from the Of the evidence humans but course, but next this subjects. which program, CLBSXX. of not supportive important only development the in are X-month results the they The of especially on of data is provide of corroborating of CLBSXX, step defining the direct outcomes quantitative for will for the trial mechanism dependent action of CDXX final something in cells, first positive from all our
We XXXX in from end of study are early XXXX. data at looking forward reporting or completed the the to
we are continued share quarter progress and execution this demonstrate objectives. to against to In pleased our closing, stated our
position financial stable. Our remain
mid Our progressing are late pipeline candidates, and a stage and cell we’ve positive programs comprising therapy CDXX three well product with pipeline projects. multiple development
have progress to we we measurable make development the to its past programs goals for continues Caladrius and quarter. pleased advancing established are accomplished the
innovative and expert remains and to and in efficient options of committed as team human to we effective need advancement experienced program, Our the health. our work treatment restore to patients bring
And operator, with now to are already that overview, questions. we take
